Agios Total Current Liabilities vs Common Stock Shares Outstanding Analysis
AGIO Stock | USD 34.79 0.21 0.60% |
Agios Pharm financial indicator trend analysis is way more than just evaluating Agios Pharm prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Agios Pharm is a good investment. Please check the relationship between Agios Pharm Total Current Liabilities and its Common Stock Shares Outstanding accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
Total Current Liabilities vs Common Stock Shares Outstanding
Total Current Liabilities vs Common Stock Shares Outstanding Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Agios Pharm Total Current Liabilities account and Common Stock Shares Outstanding. At this time, the significance of the direction appears to have strong relationship.
The correlation between Agios Pharm's Total Current Liabilities and Common Stock Shares Outstanding is 0.76. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Common Stock Shares Outstanding in the same time period over historical financial statements of Agios Pharm, assuming nothing else is changed. The correlation between historical values of Agios Pharm's Total Current Liabilities and Common Stock Shares Outstanding is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Agios Pharm are associated (or correlated) with its Common Stock Shares Outstanding. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Shares Outstanding has no effect on the direction of Total Current Liabilities i.e., Agios Pharm's Total Current Liabilities and Common Stock Shares Outstanding go up and down completely randomly.
Correlation Coefficient | 0.76 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Current Liabilities
Total Current Liabilities is an item on Agios Pharm balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Agios Pharm are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Common Stock Shares Outstanding
The total number of shares of a company's common stock that are currently owned by all its shareholders.Most indicators from Agios Pharm's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Agios Pharm current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.At this time, Agios Pharm's Sales General And Administrative To Revenue is very stable compared to the past year. As of the 17th of May 2024, Enterprise Value is likely to grow to about 1.5 B, while Selling General Administrative is likely to drop about 81.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 378.4M | 401.6M | 408.8M | 320.4M | Cost Of Revenue | 18.8M | 1.7M | 9.5M | 9.0M |
Agios Pharm fundamental ratios Correlations
Click cells to compare fundamentals
Agios Pharm Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Agios Pharm fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
Other Current Liab | 53.1M | 60.1M | 32.0M | 30.4M | 43.2M | 29.6M | |
Total Current Liabilities | 92.9M | 94.4M | 59.8M | 62.6M | 68.0M | 75.2M | |
Total Stockholder Equity | 640.5M | 399.5M | 1.3B | 1.1B | 811.0M | 564.7M | |
Other Liab | 77.4M | 50.6M | 261.3M | 3.3M | 3.8M | 3.6M | |
Property Plant And Equipment Net | 126.1M | 117.5M | 104.2M | 88.1M | 69.8M | 52.5M | |
Net Debt | 32.7M | (22.2M) | (106.0M) | (53.6M) | (16.2M) | (17.0M) | |
Retained Earnings | (1.5B) | (1.8B) | (238.8M) | (470.6M) | (822.6M) | (863.8M) | |
Accounts Payable | 21.9M | 26.8M | 16.7M | 18.6M | 9.8M | 15.9M | |
Cash | 80.9M | 127.4M | 203.1M | 139.3M | 88.2M | 83.8M | |
Non Current Assets Total | 279.0M | 216.3M | 373.5M | 405.9M | 103.3M | 178.4M | |
Non Currrent Assets Other | (279.0M) | 1.1M | 2.9M | 4.0M | 4.1M | 4.3M | |
Cash And Short Term Investments | 564.9M | 670.5M | 1.3B | 1.1B | 776.9M | 637.5M | |
Common Stock Total Equity | 58K | 68K | 69K | 71K | 81.7K | 49.5K | |
Common Stock Shares Outstanding | 60.0M | 69.0M | 60.4M | 54.8M | 55.7M | 48.8M | |
Short Term Investments | 483.9M | 445.5M | 816.9M | 643.9M | 688.7M | 428.3M | |
Liabilities And Stockholders Equity | 890.7M | 853.0M | 1.4B | 1.2B | 937.1M | 752.6M | |
Non Current Liabilities Total | 157.3M | 359.1M | 85.9M | 75.3M | 58.1M | 112.7M | |
Other Current Assets | 24.2M | (74.0M) | 11.8M | 39.0M | 35.0M | 36.8M | |
Other Stockholder Equity | 2.2B | 2.2B | 1.5B | 1.6B | 1.6B | 1.2B | |
Total Liab | 250.2M | 453.5M | 145.8M | 137.9M | 126.1M | 187.9M | |
Property Plant And Equipment Gross | 31.5M | 117.5M | 28.9M | 138.2M | 122.0M | 128.1M | |
Total Current Assets | 611.7M | 636.7M | 1.1B | 832.8M | 833.8M | 574.2M | |
Accumulated Other Comprehensive Income | 202K | 105K | (1.2M) | (12.5M) | (441K) | (463.1K) | |
Short Term Debt | 6.9M | 7.4M | 11.2M | 13.7M | 15.0M | 27.5M | |
Common Stock | 58K | 68K | 69K | 71K | 72K | 51.8K | |
Property Plant Equipment | 31.5M | 32.3M | 28.9M | 23.0M | 26.4M | 21.1M | |
Net Tangible Assets | 640.5M | 399.5M | 1.3B | 1.1B | 1.3B | 633.1M | |
Net Receivables | 15.3M | 25.4M | 4.4M | 2.2M | 2.8M | 2.7M | |
Retained Earnings Total Equity | (1.5B) | (1.8B) | (238.8M) | (470.6M) | (423.5M) | (444.7M) | |
Capital Surpluse | 2.2B | 2.2B | 2.3B | 2.4B | 2.7B | 1.7B | |
Inventory | 7.3M | 14.7M | 16.2M | 8.5M | 19.1M | 20.0M | |
Long Term Investments | 152.9M | 97.6M | 266.4M | 313.9M | 29.4M | 28.0M | |
Non Current Liabilities Other | 157.3M | 359.1M | 85.9M | 3.3M | 1.2M | 1.1M | |
Net Invested Capital | 640.5M | 399.5M | 1.3B | 1.1B | 811.0M | 833.9M | |
Net Working Capital | 518.8M | 542.3M | 1.0B | 770.1M | 765.9M | 702.8M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Agios Pharm. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Agios Stock analysis
When running Agios Pharm's price analysis, check to measure Agios Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Agios Pharm is operating at the current time. Most of Agios Pharm's value examination focuses on studying past and present price action to predict the probability of Agios Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Agios Pharm's price. Additionally, you may evaluate how the addition of Agios Pharm to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
CEOs Directory Screen CEOs from public companies around the world | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Agios Pharm's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.31) | Revenue Per Share 0.526 | Quarterly Revenue Growth 0.46 | Return On Assets (0.25) | Return On Equity (0.40) |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.